mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL

High-risk subtypes of B-cell acute lymphoblastic leukemia (B-ALL) include Philadelphia chromosome-positive (Ph+) B-ALL driven by the BCR-ABL1 oncogene and a more recently identified subtype known as BCR-ABL-like or Ph-like B-ALL. A hallmark of both Ph+ and Ph-like B-ALL is constitutive activation of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Gotesman, Moran, Vo, Thanh-Trang T., Herzog, Lee-Or, Tea, Tiffeny, Mallya, Sharmila, Tasian, Sarah K., Konopleva, Marina, Fruman, David A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814232/
https://ncbi.nlm.nih.gov/pubmed/29464092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24020
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares